2026. Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s768. DOI:https://doi.org/10.25251/bqftmw67.